Since the turn of the 20th century Bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer (NMIBC) has been in and out of favour. However, only a small proportion of patients, as low as 16%, complete what is seen as a gold standard treatment. To understand why ...
3.Zhiyong Li, Zhuowei Liu, et al.Preliminary results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).2023ASCO GU. Abstract 51...
3.Zhiyong Li, Zhuowei Liu, et al.Preliminary results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).2023ASCO GU. Abstract 51...
Intravesical bacillus Calmette-Guérin is the current first-line treatment for high-grade nonmuscle-invasive bladder cancer; however, a substantial proportion of patients are unresponsive to bacillus Calmette-Guérin treatment. While cystectomy...
E16600- Interim results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calm...
Radical cystectomy dominates BCG for bladder cancerRadical cystectomy is more cost effective than intravesical BCG therapy for the treatment of patients with bladder cancer, according to data presented at the Annual Meeting of the American Urological Association. The researchers developed a Markov Monte ...
Carol Lovegrove.Arole for death receptors in BCGtherapy for bladdercancer.Nature Clinical Practice Urology. 2005Carol Lovegrove.Arole for death receptors in BCGtherapy for bladdercancer. Nature Clinical Practice Urology . 2005C arol Lovegrove .A role for death receptors in BCG therapy for bladder ...
(TH2-polarized) lymphocytes, and number of tumour-infiltrating T-bet+ (TH1-polarized) lymphocytes—have been combined to create an immunological signature that is a statistically significant predictor of response to therapy with BCG for patients with bladder cancer and an initial diagnosis of ...
aavails itself of this opportunity to renew the assurances of its highest consideration. 用这个机会更新它的最高的考虑保证。 [translate] aReactive arthritis induced by intravesical BCG therapy for bladder cancer. intravesical BCG疗法导致的易反应的关节炎为膀胱癌。 [translate] ...
参考来源:ImmunityBioSubmits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ.新闻发布,ImmunityBio, Inc.;2022年5月23日。2022年5月31日访问。 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师...